Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.

Jeremy S Abramson; Matthew Ku; Mark Hertzberg; Hui-Qiang Huang; Christopher P Fox; Huilai Zhang; Dok Hyun Yoon; Won-Seog Kim; Haifaa Abdulhaq; William Townsend

doi:10.1016/S0140-6736(24)01774-4

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.

Identifier:nobleid.org/w1/20260515/DFD3F535

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/DFD3F535.svg?ark=w1%2F20260515%2FDFD3F535)](https://nobleid.org/work/w1/20260515/DFD3F535)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.

Identifier:nobleid.org/w1/20260515/DFD3F535

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/DFD3F535.svg?ark=w1%2F20260515%2FDFD3F535)](https://nobleid.org/work/w1/20260515/DFD3F535)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work